User:Mr. Ibrahem/Larotrectinib

Larotrectinib, sold under the brand name Vitrakvi, is a medication used to treat cancer. Specifically it is used for cases that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion. It is taken by mouth.

Common side effects include liver problems, low red blood cells, muscle pain, tiredness, low white blood cells, diarrhea, nausea, and fever. Other side effects may include numbness, tremor, and delirium. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor of TrkA, TrkB, and TrkC.

Larotrectinib was approved for medical use in the United States in 2018, Europe in 2019, and Australia in 2020. In the United Kingdom it costs the NHS about £15,000 a month as of 2021. In the United States this amount is about 34,000 USD.